MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.290
-0.120
-8.51%
Closed 19:51 05/13 EDT
OPEN
1.420
PREV CLOSE
1.410
HIGH
1.444
LOW
1.270
VOLUME
1.78M
TURNOVER
--
52 WEEK HIGH
3.790
52 WEEK LOW
0.9895
MARKET CAP
127.76M
P/E (TTM)
-1.4168
1D
5D
1M
3M
1Y
5Y
Moving Average Crossover Alert: Abeona Therapeutics (ABEO)
Zacks.com · 2d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 6d ago
64 Biggest Movers From Yesterday
Gainers
Benzinga · 05/05 09:59
Thinking about buying stock in GameStop, AMC Entertainment, Meredith Corp, Sundial Growers, or Abeona Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, MDP, SNDL, and ABEO.
PR Newswire - PRF · 05/03 13:31
MARA, BNTX, OCGN and ATOS among notable premarket gainers
Brooklyn ImmunoTherapeutics (BTX) +38%.Regional Health Properties (RHE) +21%.Gaucho Group Holdings (VINO) +15%.Ashford Hospitality Trust (AHT) +15%.Ocugen (OCGN) +13% as COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2,...
Seekingalpha · 05/03 12:26
BRIEF-Abeona Therapeutics Announces Presentation On New Preclinical Data Supporting Potential Of Stargardt Disease Treatment At ARVO 2021 Annual Meeting
reuters.com · 04/20 11:42
Abeona Therapeutics To Highlight New Data From Preclinical Research At Association For Research In Vision And Ophthalmology 2021 Annual Meeting May 1-7
Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its preclinical research will be highlighted during an oral presentation at the Association
Benzinga · 04/20 11:40
BRIEF-Abeona Appoints Two Industry Leaders As New Independent Members To Its Board Of Directors
reuters.com · 04/19 11:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABEO. Analyze the recent business situations of Abeona through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABEO stock price target is 5.67 with a high estimate of 8.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 141
Institutional Holdings: 39.17M
% Owned: 39.55%
Shares Outstanding: 99.04M
TypeInstitutionsShares
Increased
29
7.30M
New
13
554.58K
Decreased
13
4.39M
Sold Out
17
6.95M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.35%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Executive Director
Steven Rouhandeh
President/Chief Executive Officer/Chief Operating Officer/Director
Michael Amoroso
Chief Accounting Officer
Edward Carr
Chief Financial Officer/IR Contact Officer
Christine Berni-Silverstein
Director
Christine Silverstein
Independent Director
Leila Alland
Independent Director
Mark Alvino
Independent Director
Faith Charles
Independent Director
Paul Mann
Independent Director
Todd Wider
Independent Director
Donald Wuchterl
Other
Max Colao
No Data
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.